Cerevel Puts Tavapadon Into Phase III for Parkinson’s
Recruiting 1,200 Patients
The company, launched in October 2018 with neuroscience programs spun out from Pfizer and supported by $350m from Bain, believes it has a treatment that could prove effective across the full spectrum of Parkinson’s disease.
